At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 166 enrolled
Drug / intervention
LAU-7b +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults
In Brief
A Phase 2 clinical trial evaluating LAU-7b and Placebo oral capsule for Cystic Fibrosis. Completed, enrolled 166 participants across 40 sites in 3 countries.
Detailed Summary
An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesAustralia, Canada, United States
CollaboratorsCystic Fibrosis Foundation
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartNov 2018
Primary CompletionSep 2021
TodayJul 2026
First PostedAug 29, 2017
Enrollment StartNov 5, 2018
Primary CompletionSep 15, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.8 years ago
Interventions
LAU-7bdrug
LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
Placebo oral capsuledrug
Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.